{"type":"trials","record":{"id":41936,"source_id":"clinicaltrials-gov","external_id":"NCT06394232","title":"Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.","brief_summary":"The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD). The main questions it aims to answer are: * Safety and tolerability of the novel stem cell formulation * Potential efficacy of the novel stem cell formulation Participants will receive a single subretinal injection in their study eye and followed up for safety. This is an India only study and the product is developed indigenously.","overall_status":"Recruiting","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Eyestem Research Pvt. Ltd.","enrollment":54,"countries":["India"],"start_date":"2024-06-04","completion_date":"2030-12-01","last_update_date":"2024-09-24","source_url":"https://clinicaltrials.gov/study/NCT06394232","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 100 Years","comparator":null,"organization":"Eyestem Research Pvt. Ltd.","interventions":["Eyecyte-RPE™"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Fundus Autofluorescence- — Upto 12 months","Best Corrected Visual Acuity (BCVA)-Mean change from baseline in BCVA score in study eye and fellow eye. — Upto 12 mont…","Spectral-Domain Optical Coherence Tomography (SD-OCT)-Mean change from baseline in the Geographic Atrophy (GA) area in…","Fundus Photography- Changes between study eye and fellow eye — Upto 12 months","Microperimetry-Mean change from baseline in mean sensitivity — Upto 12 months","National Eye Institute-Visual Function Questionnaire Quality of Life score — Upto 12 months"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Retinal Disease","Macular Degeneration","Age-Related Macular Degeneration","Geographic Atrophy","Eye Diseases","Eyecyte-RPE™"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06394232","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-06-04 to 2030-12-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 100 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.895Z","intervention":["Eyecyte-RPE™"],"participants":54,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Fundus Autofluorescence- — Upto 12 months","Best Corrected Visual Acuity (BCVA)-Mean change from baseline in BCVA score in study eye and fellow eye. — Upto 12 mont…","Spectral-Domain Optical Coherence Tomography (SD-OCT)-Mean change from baseline in the Geographic Atrophy (GA) area in…","Fundus Photography- Changes between study eye and fellow eye — Upto 12 months","Microperimetry-Mean change from baseline in mean sensitivity — Upto 12 months","National Eye Institute-Visual Function Questionnaire Quality of Life score — Upto 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41936","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}